Sunday, July 5, 2026
Knowledge FilesSearch
Via News
Via News Knowledge File

Johnson & Johnson Services, Inc.

organization80% conf.·synced Jul 5, 2026

Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience

46
sourced metrics
1140
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Dividend Increase Streak
64years
Jul 5, 2026source
Consecutive Dividend Increase Years
64years
Jul 5, 2026source
Stock Price
228USD
Jul 5, 2026source
Quarterly Dividend Per Share
1.34USD
Jul 5, 2026source
Dividend Per Share Annualized
5.36USD
Jul 5, 2026source
Market Share
28blockbuster_products_count
Jun 8, 2026source
Dividend Growth Streak
64consecutive_years
May 19, 2026source
Portfolio Weight In Xlv
10.42percent
May 18, 2026source
Portfolio Weight In Fhlc
8.90percent
May 18, 2026source
Net Income
24USD
May 12, 2026source
Margin
20percent
May 12, 2026source
Copilot Seats Committed
90000seats
Apr 30, 2026source
International Revenue
10.7USD
Apr 15, 2026source
Eps
2.14USD_per_share
Apr 15, 2026source
Domestic Revenue
13.33USD
Apr 15, 2026source
Consecutive Dividend Increases
64years
Apr 14, 2026source
Dividend Per Share
1.34USD
Apr 14, 2026source
Free Cash Flow
1.5USD
Apr 14, 2026source

Stated objectives

Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%

source
target: 93.5-93.9 billion USD stated

Improve adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs

source
target: ~300 bps improvement stated

Achieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%

source
target: >5% revenue growth stated

Achieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44

source
target: ~$11.44 adjusted EPS stated

Submit OTTAVA robotic surgical system for regulatory approval in the United States

source
target: Regulatory submission completed stated

Achieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026

source
by 2026-01-01 00:00:00stated

Improve MedTech growth and margins by completing the pending separation of the Orthopaedics franchise

source
stated

Strengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies

source
stated

Develop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem

source
stated

J&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026

source
target: higher than 2025 growth rates by 2026-01-01 00:00:00stated

Relationship graph · 1140 connections

Developed by
466
Competes with
122
subsidiary of
69
Covered by
67
Employs
56
Owns
52
acquired by
50
regulates
35
researched at
STEMI DTU Trial
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →